S&P 500 7,408.30 -1.21% NASDAQ 25,137.69 -2.15% DOW 51,711.65 -0.97% R2K 2,940.16 -0.67% VIX 18.70 +12.38% US 10Y 4.70 +0.99% DXY 101.41 -0.02% GOLD 4,030.30 -0.40% CRUDE 91.74 -0.49%
Next Bullish Trade
Sign in
LQDA

Liquidia Corporation NCM · LQDA

$89.03 +1.99 (+2.29%)
Blow-off · +2.10σ Hot zone Grade C
+ Compare Open in Sniper

Price chart

Timeframe
Range
Fundamentals · free Click ▲ earnings markers (daily) for the day's move

Loading…

Latest bar · LQDA

Momentum reads · latest daily bar
Last
$89.03
+1.99 (+2.29%)
Mkt cap
$7.9B
Healthcare
RSI(14)
67.1
neutral
Stochastic %K
87.7
overbought
MFI(14)
70.3
neutral
ADX(14)
23.6
building

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $0.1B $0.1B $0.1B $0.1B 39.8% 46.3%
2025-12-31 $0.1B $0.0B $0.0B $0.0B 15.8% 21.5%
2025-09-30 $0.1B $-0.0B $0.0B $-0.0B -6.5% 3.3%
2025-06-30 $0.0B $-0.0B $-0.0B $-0.0B -470.5% -424.4%
2025-03-31 $0.0B $-0.0B $-0.0B $-0.0B -1229.7% -1135.4%
2024-12-31 $nanB $nanB $nanB $nanB nan% nan%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare LQDA vs peers

Line LQDA up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing LQDA no peers yet — add up to 4 below
Sector peers + LLY + UNH + JNJ + MRK + ABBV + PFE
Popular + AAPL + MSFT + NVDA + AMZN + GOOG + META + TSLA + AVGO
Matchups NVDA · AMD · AVGO · SMCI · MU AAPL · MSFT · GOOG · META · AMZN JPM · GS · MS · BAC · C TSLA · RIVN · LCID · GM · F XOM · CVX · OXY · COP

Add tickers to compare with LQDA

~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.

Earnings replay · last 20 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

DateEPS actual EPS estSurprise Next-day
2026-05-11 0.52 0.41 +28.1% +6.5%
2026-03-05 0.15 0.33 -55.1% +4.4%
2025-11-03 -0.04 -0.35 +88.7% +10.7%
2025-08-12 -0.49 -0.39 -24.8% +4.6%
2025-05-08 -0.45 -0.42 -7.1% -0.6%
2025-03-19 -0.45 -0.39 -13.9% +3.5%
2024-11-13 -0.39 -0.40 +2.2% -2.3%
2024-08-07 -0.37 -0.33 -12.1% +6.5%
2024-05-13 -0.39 -0.28 -37.0% -1.5%
2024-03-13 -0.42 -0.23 -78.7% +4.0%
2023-11-07 -0.24 -0.19 -26.3% -4.4%
2023-08-10 -0.36 -0.16 -125.0% -9.1%
2023-05-04 -0.15 -0.17 +16.6% +1.1%
2023-03-16 -0.09 -0.17 +46.0% -1.5%
2022-11-08 -0.14 -0.19 +26.3% +0.4%
2022-08-11 -0.15 -0.22 +31.8% +27.9%
2022-05-12 -0.28 -0.20 -42.5% +13.9%
2022-03-17 -0.23 -0.13 -81.6% +5.9%
2021-11-03 -0.14 -0.15 +6.7% -0.2%
2021-08-10 -0.13 -0.16 +18.8% -2.1%

Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
LQDA ★ $8B 494.6 15.3 27.5 169.0 72.4 91.8% 4158.5% — 0.12%
LLY $1,057B 41.3 26.4 — 30.3 34.0 82.8% 55.5% 169.9% 0.87%
UNH $385B 32.5 18.9 0.9 17.6 3.7 19.5% 0.4% 61.5% 5.92%
JNJ $624B 29.7 20.2 6.4 18.9 7.7 68.1% 6.6% -1.0% —
MRK $322B 35.9 13.5 — 12.4 7.0 76.7% 4.9% — 4.36%
ABBV $454B 125.3 15.8 7.2 17.3 -68.2 72.0% 12.4% -46.2% 4.58%
PFE $143B 18.9 8.8 — 7.6 1.6 74.8% 5.4% -10.1% 8.68%
TMO $213B 28.9 21.0 — 20.9 4.1 40.9% 6.2% 11.3% 2.60%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 43.56%

HolderShares% out
Farallon Capital Management LLC 8,656,038 9.73%
Caligan Partners, LP 8,118,892 9.13%
Blackrock Inc. 5,489,144 6.17%
Findell Capital Management LLC 3,502,112 3.94%
Vanguard Capital Management LLC 2,926,945 3.29%
Opaleye Management Inc. 2,545,000 2.86%
Bank of America Corporation 2,287,792 2.57%
Geode Capital Management, LLC 1,928,969 2.17%
State Street Corporation 1,881,599 2.12%
MPM Bioimpact LLC 1,405,158 1.58%

Insider activity · 90d

0 buys / 15 sells · ratio 0.0 · Finnhub

  • Bloch Stephen M SELL 701,477 @ $80.66
  • Bloch Stephen M SELL 702,033 @ $79.98
  • Bloch Stephen M SELL 776,477 @ $79.55
  • Krepp Sarah SELL 117,178 @ $71.52
  • Krepp Sarah SELL 124,484 @ $71.39
  • Khindri Sanjeev SELL 65,947 @ $71.52
  • Khindri Sanjeev SELL 67,048 @ $71.39
  • Schundler Russell SELL 605,962 @ $71.52
  • Schundler Russell SELL 619,654 @ $71.39
  • Saggar Rajeev SELL 171,799 @ $71.52

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low
$60.0
Mean
$74.25
High
$109.0
Analysts
8
Recommendation distribution · period 2026-07-01
5
7
2
Revision trend (2026-04-01 → 2026-07-01): net 12 → 12 0 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

FormFiled DescriptionAction
4 2026-07-22 OWNERSHIP DOCUMENT view ·
4 2026-07-14 OWNERSHIP DOCUMENT view ·
4 2026-07-14 OWNERSHIP DOCUMENT view ·
4 2026-07-14 OWNERSHIP DOCUMENT view ·
4 2026-07-14 OWNERSHIP DOCUMENT view ·
4 2026-07-14 OWNERSHIP DOCUMENT view ·
4 2026-07-14 OWNERSHIP DOCUMENT view ·
4 2026-07-14 OWNERSHIP DOCUMENT view ·
4 2026-07-14 OWNERSHIP DOCUMENT view ·
4 2026-07-14 OWNERSHIP DOCUMENT view ·
4 2026-07-08 OWNERSHIP DOCUMENT view ·
4 2026-07-06 OWNERSHIP DOCUMENT view ·
4 2026-06-24 OWNERSHIP DOCUMENT view ·
4 2026-06-18 Insider transaction (Form 4) view ·
4 2026-06-18 OWNERSHIP DOCUMENT view ·
4 2026-06-18 OWNERSHIP DOCUMENT view ·
4 2026-06-18 OWNERSHIP DOCUMENT view ·
4 2026-06-18 OWNERSHIP DOCUMENT view ·
4 2026-06-18 OWNERSHIP DOCUMENT view ·
4 2026-06-18 OWNERSHIP DOCUMENT view ·
4 2026-06-18 Insider transaction (Form 4) view ·
8-K 2026-06-17 FORM 8-K view ·
4 2026-06-16 OWNERSHIP DOCUMENT view ·
4 2026-06-15 OWNERSHIP DOCUMENT view ·
4 2026-06-12 OWNERSHIP DOCUMENT view ·
4 2026-06-10 OWNERSHIP DOCUMENT view ·
4 2026-06-10 OWNERSHIP DOCUMENT view ·
4 2026-06-08 Insider transaction (Form 4) view ·
8-K 2026-06-08 FORM 8-K view ·
4 2026-06-08 OWNERSHIP DOCUMENT view ·
4 2026-06-03 OWNERSHIP DOCUMENT view ·
4 2026-06-03 OWNERSHIP DOCUMENT view ·
4 2026-05-28 OWNERSHIP DOCUMENT view ·
4 2026-05-26 OWNERSHIP DOCUMENT view ·
4 2026-05-26 OWNERSHIP DOCUMENT view ·
4 2026-05-20 Insider transaction (Form 4) view ·
4 2026-05-20 OWNERSHIP DOCUMENT view ·
4 2026-05-15 OWNERSHIP DOCUMENT view ·
4 2026-05-13 OWNERSHIP DOCUMENT view ·
4 2026-05-12 OWNERSHIP DOCUMENT view ·
10-Q 2026-05-11 10-Q view ·
8-K 2026-05-11 FORM 8-K view ·
4 2026-05-07 OWNERSHIP DOCUMENT view ·
4 2026-04-29 OWNERSHIP DOCUMENT view ·
4 2026-04-29 OWNERSHIP DOCUMENT view ·
DEF 14A 2026-04-24 FORM DEF 14A view ·
4 2026-04-21 OWNERSHIP DOCUMENT view ·
4 2026-04-16 OWNERSHIP DOCUMENT view ·
4 2026-04-16 OWNERSHIP DOCUMENT view ·
4 2026-04-14 OWNERSHIP DOCUMENT view ·
4 2026-04-14 OWNERSHIP DOCUMENT view ·
4 2026-04-14 OWNERSHIP DOCUMENT view ·
4 2026-04-14 OWNERSHIP DOCUMENT view ·
4 2026-04-14 OWNERSHIP DOCUMENT view ·
4 2026-04-14 OWNERSHIP DOCUMENT view ·
4 2026-04-14 OWNERSHIP DOCUMENT view ·
4 2026-04-14 OWNERSHIP DOCUMENT view ·
4 2026-04-13 OWNERSHIP DOCUMENT view ·
4 2026-04-13 OWNERSHIP DOCUMENT view ·
4 2026-03-30 OWNERSHIP DOCUMENT view ·

About LQDA

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vect…

Options picks · LQDA

ITM + OTM ideas from the latest scan

Loading…

Congress trades · LQDA

STOCK Act disclosures

Loading…

SEC filings & insiders · LQDA

EDGAR · live

Loading…

Holders · LQDA

Institutions & insider activity

Loading…